Paradigm guiding to tapering or discontinuation of biologic and targeted synthetic disease‐modifying antirheumatic drugs in the treatment of patients with rheumatoid arthritis: Results from a local prospective study

We prospectively conduct the current study to figure out predicting factors whether biologic and targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) can be discontinued or tapered in patients with rheumatoid arthritis (RA).

[1]  Lara A. Kahale,et al.  2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2021, Arthritis & rheumatology.

[2]  G. Cavalli,et al.  Biologic discontinuation strategies and outcomes in patients with rheumatoid arthritis , 2019, Expert review of clinical immunology.

[3]  D. Aletaha,et al.  Predictors of successful discontinuation of biologic and targeted synthetic DMARDs in patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review. , 2019, Rheumatology.

[4]  G. L. La Paglia,et al.  Extra-articular rheumatoid arthritis. , 2018, Reumatismo.

[5]  J. Smolen,et al.  Diagnosis and Management of Rheumatoid Arthritis: A Review , 2018, JAMA.

[6]  J. Bijlsma,et al.  Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study - a randomised controlled pragmatic non-inferiority strategy trial , 2017, Annals of the rheumatic diseases.

[7]  Tsutomu Takeuchi,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update , 2010, Annals of the rheumatic diseases.

[8]  E. Naredo,et al.  Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions , 2016, Annals of the rheumatic diseases.

[9]  C. Allaart,et al.  Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Multicenter, Open‐Label Randomized Controlled Trial , 2016, Arthritis & rheumatology.

[10]  F. Tubach,et al.  Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study) , 2015, Annals of the rheumatic diseases.

[11]  M. Dougados,et al.  Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force , 2015, Annals of the rheumatic diseases.

[12]  M. Leirisalo-Repo,et al.  Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis , 2015, Annals of the rheumatic diseases.

[13]  藤井隆夫.  Treating rheumatoid arthritis to the target―関節リウマチの治療戦略をここまで変えたものは何か― , 2016 .

[14]  J. Bijlsma,et al.  Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial , 2015, BMJ : British Medical Journal.

[15]  H. Genant,et al.  Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis , 2014, Annals of the rheumatic diseases.

[16]  M. Dougados,et al.  Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study , 2013, Annals of the rheumatic diseases.

[17]  Raveendhara R. Bannuru,et al.  American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2015 .

[18]  P. Emery,et al.  Sustained remission with etanercept tapering in early rheumatoid arthritis. , 2014, The New England journal of medicine.

[19]  Y. Saeki,et al.  Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study , 2013, Modern rheumatology.

[20]  Jinoos Yazdany,et al.  Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice , 2012, Arthritis care & research.

[21]  S. Ito,et al.  Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules , 2012, Annals of the rheumatic diseases.

[22]  D. M. van der Heijde.  Remission by imaging in rheumatoid arthritis: should this be the ultimate goal? , 2012, Annals of the rheumatic diseases.

[23]  C. Gabay,et al.  Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients , 2012, Annals of the rheumatic diseases.

[24]  M. Cross,et al.  'I'm hurting, I want to kill myself': rheumatoid arthritis flare is more than a high joint count--an international patient perspective on flare where medical help is sought. , 2012, Rheumatology.

[25]  B. Dijkmans,et al.  Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study , 2011, Annals of the rheumatic diseases.

[26]  J. Berthelot,et al.  Weekly home self-assessment of RAPID-4/3 scores in rheumatoid arthritis: a 6-month study in 26 patients. , 2010, Joint, bone, spine : revue du rhumatisme.

[27]  P. Emery,et al.  Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis. , 2010, Rheumatology.

[28]  A. Silman,et al.  UvA-DARE (Digital Academic Repository) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative Aletaha, , 2010 .

[29]  P. Emery,et al.  Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? , 2010, Annals of the rheumatic diseases.

[30]  T. Mimori,et al.  Extended Report , 2022 .

[31]  I. Christensen,et al.  Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. , 2010, Arthritis and rheumatism.

[32]  C. Gabay,et al.  Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. , 2009, Arthritis and rheumatism.

[33]  Ronald Anderson,et al.  Predictors of discontinuation of tumor necrosis factor inhibitors in patients with rheumatoid arthritis. , 2008, The Journal of rheumatology.

[34]  J. Gómez-Reino,et al.  Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period , 2006, Arthritis research & therapy.

[35]  Maarten Boers,et al.  The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. , 2004, Arthritis and rheumatism.

[36]  M. Prevoo,et al.  Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. , 1996, British journal of rheumatology.

[37]  M. Prevoo,et al.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[38]  C. Werning.  [Rheumatoid arthritis]. , 1983, Medizinische Monatsschrift fur Pharmazeuten.